Table 3 Clinical response and remission: group II.
| Parameter | Day | Placebo | Fontolizumab | |
|---|---|---|---|---|
| 4 mg/kg (p value*) | 10 mg/kg (p value*) | |||
| Clinical response (CDAI drop of ⩾100 points) | 42 | 10/26 (39%) | 19/32 (59%) (0.19) | 20/31 (65%) (0.07) |
| 56 | 9/26 (35%) | 22/32 (69%) (0.02) | 20/30 (67%) (0.03) | |
| Clinical remission (CDAI ⩽150) | 42 | 4/26 (15%) | 15/32 (47%) (0.01) | 14/31 (45%) (0.02) |
| 56 | 7/26 (27%) | 13/32 (41%) (0.41) | 16/30 (53%) (0.06) | |
*Compared with placebo group.
CDAI, Crohn's disease activity index.